Vizz (aceclidine HCl)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Instill one drop in each eye, wait 2 minutes and instill a second drop in each eye once daily from the same single-dose vial.

Remove contact lenses prior to instillation; may re-insert 10 minutes after installation.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

None.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• Iritis

The most common adverse reactions were instillation site irritation (20%), dim vision (16%), and headache (13%).

There are no severe adverse reactions for this drug.

More Frequent

• Headache disorder
• Ocular irritation
• Visual changes

Less Frequent

• Conjunctival hyperemia

No enhanced messaging available.

Presbyopia does not occur in the pediatric population.

There are no adequate and well controlled studies of aceclidine administration in pregnant women to inform a drug associated risk. In animal reproduction studies, oral administration of aceclidine to pregnant rats and rabbits throughout organogenesis and lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses.

There is no information regarding the presence of aceclidine or its metabolite in human or animal milk, the effects on breastfed infants or the effects on milk production to inform the risk of aceclidine to an infant during lactation.

Systemic levels of aceclidine and its metabolites following topical ocular administration are low, and it is not known whether measurable levels of aceclidine or its metabolites would be present in human milk following topical ocular administration.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for aceclidine and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.

No overall differences in safety or effectiveness of aceclidine have been observed between patients 65 years of age and older and younger adult patients.